Insilico Medicine

Private

#Fibrosis #Oncology #Immunology #Generative AI Platforms

Insilico Medicine is an end-to-end generative artificial intelligence-driven drug discovery company connecting biology, chemistry, and clinical trials analysis.

Company Info

Sector:AI Drug Discovery / TechBio

Headquarters:Boston, Massachusetts, USA (with offices in New York and Hong Kong)

Founded:2014

Website:insilico.com

Funding Round:Series D-2

Total Funding:$415M

Funding & Investor Relations

Notable Investors

Warburg Pincus
Qiming Venture Partners
Deerfield Management
B Capital Group
Maison Capital
OrbiMed

IPO Outlook / Plans

Reportedly planning to file for a Hong Kong Stock Exchange (HKEX) listing in late 2026 / early 2027, depending on market conditions.

Upcoming Milestones & Key Dates

August 15, 2026

Clinical Trial

Interim Phase 2 Safety & Tolerability Data Release for ISM001-055

October 22, 2026

Conference

Keynote Lecture at Global AI in Drug Discovery Summit

Clinical Development Pipeline

ISM001-055

Target: TRAF2 & NCK-interacting kinase (TNIK)

Idiopathic Pulmonary Fibrosis (IPF)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ISM3091

Target: USP1 Inhibitor

Solid Tumors (BRCA Mutated)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ISM8207

Target: QPCTL Inhibitor

Advanced Solid Tumors and B-cell Lymphoma

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Insilico’s partner pens $177M pact for ‘mass market’ CNS target ↗

Insilico Medicine Licensing deals central nervous system China Pharma platform company China Medical System Holdings (CMS) has tapped up existing partner Insilico for a 1.2 billion yuan ($177 million) collaboration aimed at a “mass-market” central nervous system (CNS) indication. The pact will involve Insilico’s AI platform PandaOmics joining forces with CMS’ “experienced R&D team and deep therapeutic expertise,” according to the July 12 release. While the companies didn’t divulge the specific C

Business & Strategy•Jun 22, 2026•BioSpace

Insilico's AI design engine bags Korean biotech deal worth possible $2.5B+ ↗

Insilico Medicine signs a deal with a Korean biotech to use its AI-driven drug design engine, with biobucks potentially exceeding $2.5 billion.

Business & Strategy•Jun 18, 2026•Insilico Medicine (company press release)

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Potential $2.5B+ ↗

Insilico Medicine and SK Biopharmaceuticals achieved a major AI-powered drug discovery collaboration worth potentially $2.5 billion+, leveraging Insilico's AI drug discovery platform to develop novel therapeutics.

Therapeutics Development•May 31, 2026•PR Newswire

Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib for IPF ↗

Insilico Medicine announced publication of Phase IIa results in Nature Medicine for rentosertib (INS018_055), the novel TNIK inhibitor for idiopathic pulmonary fibrosis (IPF). The drug was discovered and designed with the company's pioneering AI approach. Phase 2 trials are ongoing.

Leadership Team

Alex Zhavoronkov, Ph.D.

Founder and Chief Executive Officer

Feng Ren, Ph.D.

Co-Chief Executive Officer and Chief Scientific Officer

Petrina Kamya, Ph.D.

Vice President and Global Head of AI Platforms

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →